Defective Glucose Monitors Flagged—Serious Risk

Person using a blood glucose meter to check their levels

Someone stole defective glucose monitors headed for the scrapyard, resold them to diabetics who needed accurate readings to stay alive, and the Food and Drug Administration (FDA) had to issue a public warning to stop the damage.

Story Snapshot

Two specific lots of Dexcom G7 continuous glucose monitors were stolen during the disposal process and resold to unsuspecting patients through unauthorized channels.
One stolen lot carries a risk of incomplete sterilization and possible skin infection; the other had elevated internal failure rates that could leave users with no glucose readings at all.
The FDA classified this as a Class 1 device recall, the most serious category, meaning the agency determined use of these devices could cause serious injury or death.
Dexcom is offering free replacements and has pledged to pursue legal accountability against those responsible for the theft and resale.

Defective Devices Meant for Destruction Ended Up on Patients’ Arms

Dexcom identified two lots of its G7 continuous glucose monitoring sensors, lot numbers 1725204004 and 1725069002, as having been stolen during the disposal process and subsequently sold to real patients through unauthorized distribution channels. These were not products that slipped through a quality gap. They were products that had already been rejected, flagged as scrap, and designated for destruction. Someone intercepted them before that destruction could happen and turned them into profit at the expense of diabetic patients who had no idea what they were putting on their bodies.

The unauthorized seller linked to this scheme was identified as Pharmsource LLC. Dexcom discovered the diversion through its own internal quality and accounting reviews, which is actually a credit to the company’s oversight systems. The moment they confirmed the theft and resale, Dexcom issued an urgent medical device correction notification to affected parties and notified the FDA. On May 12, 2025, that formal notification went out, and by June 9, 2025, the FDA had escalated the situation to a full Class 1 recall of the Dexcom G7 glucose receiver associated with these lots.

One Lot Could Infect You, the Other Could Go Silent When You Need It Most

The two stolen lots carry distinctly different but equally serious risks. Lot 1725204004 is the one that should alarm anyone who received it most immediately. Dexcom warned that this lot may carry an increased risk of incomplete sterilization and possible skin infection. For a wearable sensor that penetrates the skin to measure interstitial glucose levels, incomplete sterilization is not a minor paperwork problem. It is a direct pathway for bacterial contamination into the body of someone who may already have compromised circulation or immune response due to diabetes.

Lot 1725069002 presents a different but equally dangerous failure mode. This lot had elevated internal testing failures, meaning the sensors were statistically more likely to simply stop working. For a diabetic patient managing insulin dosing based on continuous glucose monitor readings, a device that goes silent without warning is not just inconvenient. It is a potential medical emergency. A missed hypoglycemic event can cause loss of consciousness. A missed hyperglycemic spike can accelerate organ damage. The device’s entire value proposition is real-time accuracy, and these sensors could not reliably deliver it.

This Is Not a Manufacturing Story, It Is a Supply Chain Crime Story

The instinct when reading about a device recall is to blame the manufacturer. That instinct is wrong here, and the distinction matters enormously. Dexcom did not ship defective product. Dexcom rejected defective product, scheduled it for destruction, and had it stolen before that destruction could occur. The failure belongs entirely to whoever orchestrated the theft and to Pharmsource LLC for putting dangerous, already-condemned medical devices back into the hands of vulnerable patients for profit. Dexcom has pledged to hold the responsible parties legally accountable, and that accountability cannot come fast enough.

$DXCM
Dexcom warns of stolen glucose monitors being sold by unauthorized dealers

-Dexcom warned that some lots of its G7 wearable glucose monitors were stolen on their way to the scrapyard and were sold by a third-party vendor.
https://t.co/RjyPdadDCR

— stock setter (@MarcJacksonLA) May 28, 2026

As of the time of reporting, no severe adverse events had been formally linked to these stolen sensors. That is genuinely good news, but it does not reduce the urgency of action for anyone who may have received devices from these lots. Dexcom is offering free replacements to affected users. If you use a Dexcom G7 and received your sensors from any non-pharmacy, non-authorized source, check your lot numbers against 1725204004 and 1725069002 immediately. Stop using the device if you have a match and contact Dexcom directly. The company’s own internal review caught this problem. Let their replacement process finish the job.